# Systemic Light Chain Amyloidosis - Panel Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Medical Specialty</th>
<th>Institution/Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shaji K. Kumar, MD/Chair †</td>
<td>‡</td>
<td>Mayo Clinic Cancer Center</td>
</tr>
<tr>
<td>Natalie S. Callander, MD/Vice Chair †</td>
<td>‡</td>
<td>University of Wisconsin Carbone Cancer Center</td>
</tr>
<tr>
<td>Melissa Alsina, MD †</td>
<td>†</td>
<td>Moffitt Cancer Center</td>
</tr>
<tr>
<td>Djordje Atanackovic, MD †</td>
<td>‡</td>
<td>Huntsman Cancer Institute at the University of Utah</td>
</tr>
<tr>
<td>J. Sybil Biermann, MD ¶</td>
<td></td>
<td>University of Michigan Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Jorge Castillo, MD †</td>
<td>‡</td>
<td>Dana-Farber/Brigham and Women's Cancer Center</td>
</tr>
<tr>
<td>Jason C. Chandler, MD †</td>
<td></td>
<td>St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center</td>
</tr>
<tr>
<td>Caitlin Costello, MD †</td>
<td>‡</td>
<td>UC San Diego Moores Cancer Center</td>
</tr>
<tr>
<td>Matthew Faiman, MD ‡</td>
<td></td>
<td>Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute</td>
</tr>
<tr>
<td>Henry C. Fung, MD ‡</td>
<td>‡</td>
<td>Fox Chase Cancer Center</td>
</tr>
<tr>
<td>Kelly Godby, MD †</td>
<td></td>
<td>University of Alabama at Birmingham Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Craig Hofmeister, MD, MPH †</td>
<td>‡</td>
<td>The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute</td>
</tr>
<tr>
<td>Leona Holmberg, MD, PhD †</td>
<td>‡</td>
<td>Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance</td>
</tr>
<tr>
<td>Sarah Holstein, MD, PhD †</td>
<td>‡</td>
<td>Fred &amp; Pamela Buffett Cancer Center/University of Nebraska Medical Center</td>
</tr>
<tr>
<td>Carol Ann Huff, MD †</td>
<td></td>
<td>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</td>
</tr>
<tr>
<td>Yubin Kang, MD †</td>
<td></td>
<td>Duke Cancer Institute</td>
</tr>
<tr>
<td>Adetola Kassim, MD, MS †</td>
<td>‡</td>
<td>Vanderbilt-Ingram Cancer Center</td>
</tr>
<tr>
<td>Michaela Liedtke, MD †</td>
<td></td>
<td>Stanford Cancer Institute</td>
</tr>
<tr>
<td>Ehsan Malek, MD</td>
<td></td>
<td>Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute</td>
</tr>
<tr>
<td>Thomas Martin, MD</td>
<td></td>
<td>UCSF Helen Diller Family Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Vishala T. Neppalli, MD</td>
<td></td>
<td>Roswell Park Cancer Institute</td>
</tr>
<tr>
<td>James Omel, MD</td>
<td></td>
<td>Patient Advocate</td>
</tr>
<tr>
<td>Noopur Raje, MD †</td>
<td>‡</td>
<td>Dana-Farber/Brigham and Women's Cancer Center</td>
</tr>
<tr>
<td>Seema Singhal, MD †</td>
<td></td>
<td>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</td>
</tr>
<tr>
<td>George Somlo, MD †</td>
<td>‡</td>
<td>City of Hope Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Keith Stockerl-Goldstein, MD †</td>
<td>‡</td>
<td>Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</td>
</tr>
<tr>
<td>Donna Weber, MD †</td>
<td>‡</td>
<td>The University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Joachim Yahalom, MD §</td>
<td></td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
</tbody>
</table>

**NCCN Staff**
- Rashmi Kumar, PhD
- Dorothy A. Shead, MS

**NCCN Guidelines Panel Disclosures**
- † Medical oncology
- ‡ Hematology
- ¥ Bone marrow transplantation
- ¶ Surgery/Surgical oncology
- ¶§ Radiotherapy/Radiation oncology
- Æ Internal medicine
- * Discussion section writing committee
NCCN guidelines for Systemic Light Chain Amyloidosis - Table of Contents

NCCN Systemic Light Chain Amyloidosis Panel Members

Summary of Guidelines Updates (UPDATES)

Initial Diagnostic Workup (AMYL-1)

Clinical Findings and Primary Treatment (AMYL-2)

Systemic Light Chain Amyloidosis Therapy (AMYL-A)

Definition of Organ Involvement Based on Amyloidosis Consensus Criteria (AMYL-B)

Definition of Organ and Hematologic Response and Progression Criteria (AMYL-C)

Clinical Trials: NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN member institutions, click here: nccn.org/clinical_trials/physician.html.

NCCN Categories of Evidence and Consensus: All recommendations are Category 2A unless otherwise indicated.

See NCCN Categories of Evidence and Consensus.

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2017.
Updates in Version 1.2018 of the NCCN Guidelines for Systemic Light Chain Amyloidosis from Version 1.2017 include:

**AMYL-1**
- Initial diagnostic workup:
  - Modified:
    - "CBC differential with platelet count"
    - “Serum BUN/creatinine, electrolytes, albumin, and calcium”
    - "Creatinine clearance (calculated or measured directly)"
    - “Serum uric acid”
    - “Serum quantitative immunoglobulins, serum protein electrophoresis (SPEP), serum immunofixation electrophoresis (SIFE)”
    - “24-h urine for total protein, urine protein electrophoresis (UPEP), urine immunofixation electrophoresis (UIFE)”
  - Added: “Chest CT without contrast as indicated.”
  - Moved “Mass spectrometry of observed amyloid deposits”, to be included in footnote “b.”
  - Modified footnote “b”: “It is essential to confirm that patients have primary systemic amyloidosis rather than hereditary amyloidosis, senile wildtype ATTR amyloidosis, or secondary amyloidosis. The amyloid deposits should be confirmed to be composed of light chains using immunohistochemistry or mass spectrometry. Immunohistochemistry for transthyretin or serum amyloid A component should be performed if kappa and lambda stains are negative.”
- Added a new footnote to “Abdominal fat pad aspirate.”
- New footnote “e”: “Alternate sites could include rectal or minor salivary gland biopsy.”
- Clarified “Ultrasound or CT scan to document craniocaudal liver span” by adding “abdominal” before ultrasound and CT scan.

**AMYL-2, continued**
- New footnote “i”: “Organ transplant, as clinically indicated.”
- Split “Treatment” section into “Treatment of Newly Diagnosed Disease” and “Relapsed/Refractory Disease.”
- Removed regimens from this page and added a link to a new page “Systemic light chain amyloidosis therapy.”

**AMYL-A**
- “Systemic Light Chain Amyloidosis Therapy” is a new page.
- Removed the following regimens and corresponding references:
  - Cyclophosphamide/thalidomide/dexamethasone
  - Thalidomide/dexamethasone
- New footnote “1”: “Consider oral doxycycline as adjuvant to standard systemic therapy”
- New footnote “h”: “In those patients with very low tumor burden. If not a candidate for SCT, they should be reassessed after 2 cycles of systemic therapy.”
INITIAL DIAGNOSTIC WORKUP

Clinical and amyloid-related assessment
• History and physical
• Orthostatic vital signs
• Chest x-ray
• Skeletal survey

Laboratory evaluation (directed toward commonly affected organ systems)
• CBC differential with platelet count
• Prothrombin time (PT), partial thromboplastin time (PTT), and Factor X (if indicated)
• Serum BUN/creatinine, electrolytes, albumin, and calcium
• Creatinine clearance (calculated or measured directly)
• Serum uric acid
• Serum quantitative immunoglobulins, serum protein electrophoresis (SPEP), and serum immunofixation electrophoresis (SIFE)
• 24-h urine for total protein, urine protein electrophoresis (UPEP), and urine immunofixation electrophoresis (UIFE)
• Serum free light chain (FLC) assay
• NT-proBNP,a troponin T
• Alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin

Pathologic evaluationb,c
• Bone marrow aspirate and biopsyd
• Plasma cell FISH
• Abdominal fat pad aspiratee
• Involved organ biopsy as clinically indicated

Special testing based on organ system involvement
• Cardiac
  ‣ ECG
  ‣ Echocardiogram with strain assessment
  ‣ Cardiac MRI (in certain circumstances)
• Liver and GI tract
  ‣ Stool guaiacse
  ‣ Gastric emptying scan (if gastroparesis present)
  ‣ Abdominal ultrasound or abdominal CT scan to document craniocaudal liver span
• Peripheral nervous system
  ‣ Electromyography (EMG) (if clinically significant peripheral neuropathy)/nerve conduction studies
• Other
  ‣ Endocrine testing: Thyroid-stimulating hormone (TSH), cortisol
  ‣ Pulmonary testing: Pulmonary function tests
  ‣ Chest CT without contrast as indicated

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

a If NT-proBNP is not available, BNP can be performed.

b It is essential to confirm that patients have primary systemic amyloidosis rather than hereditary amyloidosis, wildtype ATTR amyloidosis, or secondary amyloidosis. The amyloid deposits should be confirmed to be composed of light chains using immunohistochemistry or mass spectrometry. Immunohistochemistry for transthyretin or serum amyloid A component should be performed if kappa and lambda stains are negative.

c Identification of light chains in the serum or urine without confirmation of the amyloid composition in tissue is not adequate as patients with other forms of amyloidosis may have an unrelated MGUS. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-1791.

d Congo red staining for amyloid. Congo stain does not differentiate between types of amyloid.

e Alternate sites could include rectal or minor salivary gland biopsy.
### CLINICAL FINDINGS

| Organ involvement based on amyloidosis consensus criteria<sup>f</sup> | Evaluate for stem cell transplant (SCT) candidacy<sup>h</sup> | Clinical Trial or Therapy for newly diagnosed disease<sup>i</sup> (see AMYL-A) and Best supportive care | Therapy for relapsed/refractory disease (See AMYL-A) and Best supportive care | See NCCN Guidelines for Palliative Care |

### TREATMENT OF NEWLY DIAGNOSED DISEASE<sup>f,g</sup>

- Evaluate for stem cell transplant (SCT) candidacy
- Clinical Trial or Therapy for newly diagnosed disease (see AMYL-A) and Best supportive care
- Organ transplant, as clinically indicated.

### RELAPSED/REFRACTORY DISEASE<sup>g</sup>

- Therapy for relapsed/refractory disease (See AMYL-A)
- Best supportive care
- See NCCN Guidelines for Palliative Care

---

<sup>f</sup>See Definition of Organ Involvement and Response to Treatment Based on Amyloidosis Consensus Criteria (AMYL-B)

<sup>g</sup>Definition of Organ and Hematologic Response and Progression Criteria (AMYL-C).

<sup>h</sup>In those patients with very low tumor burden. If not a candidate for SCT at initial diagnosis, reassess after 2 cycles of systemic therapy.

<sup>i</sup>Organ transplant, as clinically indicated.

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
NEWLY DIAGNOSED DISEASE¹

REGIMENS FOR TRANSPLANT ELIGIBLE CANDIDATES²

See References for Treatment Options (AMYL-A)

Preferred Regimen:
• Bortezomib³/cyclophosphamide/dexamethasone

Other Regimen:
• Bortezomib³ ± dexamethasone
• Bortezomib³/melphalan/dexamethasone
• Lenalidomide/cyclophosphamide/dexamethasone
• Lenalidomide/dexamethasone
• Oral melphalan/dexamethasone

REGIMENS FOR TRANSPLANT INELIGIBLE CANDIDATES

(if not a candidate for stem cell transplant at initial diagnosis, reassess after 2 cycles of systemic therapy)

See References for Treatment Options (AMYL-A)

Preferred Regimen:
• Bortezomib³/cyclophosphamide/dexamethasone
• Oral melphalan/dexamethasone

Other Regimen:
• Bortezomib³ ± dexamethasone
• Bortezomib³/melphalan/dexamethasone
• Lenalidomide/cyclophosphamide/dexamethasone
• Lenalidomide/dexamethasone

¹Consider oral doxycycline as adjuvant to standard systemic therapy.

²Patients eligible for stem cell transplant can elect to collect stem cells and delay transplant to a later line of therapy. The dose of melphalan as part of stem cell transplantation can be adjusted based on factors such as age, presence/absence of cardiac involvement, and number of organs involved. These risk-adapted approaches have not been evaluated in randomized studies. Skinner M, Sanchorawala V, Seldin D, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.


³Recommend herpes zoster prophylaxis for patients treated with bortezomib.
SYSTEMIC LIGHT CHAIN AMYLOIDOSIS THERAPY

RELAPSED/REFRACTORY DISEASE

See References for Treatment Options (AMYL-A)
- Consider initial therapy, especially if relapse-free for several years
- High-dose melphalan\(^4\) with stem cell transplant
- Bortezomib\(^3\) ± dexamethasone
- Bortezomib\(^3\)/melphalan/dexamethasone
- Lenalidomide/cyclophosphamide/dexamethasone
- Lenalidomide/dexamethasone
- Oral melphalan/dexamethasone
- Pomalidomide/dexamethasone

\(^1\)Consider oral doxycycline as adjuvant to standard systemic therapy.

\(^2\)Recommend herpes zoster prophylaxis for patients treated with bortezomib.

\(^3\)The dose of melphalan as part of stem cell transplantation can be adjusted based on factors such as age, presence/absence of cardiac involvement, and number of organs involved. These risk-adapted approaches have not been evaluated in randomized studies. Skinner M, Sanchorawala V, Seldin D, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.


REFERENCES FOR TREATMENT OPTIONS

- **Bortezomib/cyclophosphamide/dexamethasone**

- **Bortezomib ± dexamethasone**

- **Bortezomib/melphalan/dexamethasone**

- **High-dose melphalan with stem cell transplant**
REFERENCES FOR TREATMENT OPTIONS

- **Lenalidomide/cyclophosphamide/dexamethasone**

- **Lenalidomide/dexamethasone**

- **Oral melphalan/dexamethasone**

- **Pomalidomide/dexamethasone**
### DEFINITION OF ORGAN INVOLVEMENT BASED ON AMYLOIDOSIS CONSENSUS CRITERIA*

#### Organ Involvement

<table>
<thead>
<tr>
<th>Organ Involvement</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Kidney</strong></td>
<td>24-h urine protein &gt;0.5 g/d, predominantly albumin</td>
</tr>
<tr>
<td><strong>Heart</strong></td>
<td>Echo: mean wall thickness &gt;12 mm, no other cardiac cause or an elevated NT-ProBNP (&gt;332 ng/L) in the absence of renal failure or atrial fibrillation</td>
</tr>
<tr>
<td><strong>Liver</strong></td>
<td>Total liver span &gt;15 cm in the absence of heart ure or alkaline phosphatase &gt;1.5 times institutional upper limit of normal</td>
</tr>
<tr>
<td><strong>Nerve</strong></td>
<td>Peripheral: clinical; symmetric lower extremity sensorimotor peripheral neuropathy</td>
</tr>
<tr>
<td></td>
<td>Autonomic: gastric-emptying disorder, pseudo-obstruction, voiding dysfunction not related to direct organ infiltration</td>
</tr>
<tr>
<td><strong>Gastrointestinal tract</strong></td>
<td>Direct biopsy verification with symptoms</td>
</tr>
<tr>
<td><strong>Lung</strong></td>
<td>Direct biopsy verification with symptoms, interstitial radiographic pattern</td>
</tr>
<tr>
<td><strong>Soft tissue</strong></td>
<td>Tongue enlargement, clinical</td>
</tr>
<tr>
<td></td>
<td>Arthropathy</td>
</tr>
<tr>
<td></td>
<td>Claudication, presumed vascular amyloid</td>
</tr>
<tr>
<td></td>
<td>Skin</td>
</tr>
<tr>
<td></td>
<td>Myopathy by biopsy or pseudohypertrophy</td>
</tr>
<tr>
<td></td>
<td>Lymph node (may be localized)</td>
</tr>
<tr>
<td></td>
<td>Carpal tunnel syndrome</td>
</tr>
</tbody>
</table>

Revised Consensus Criteria for amyloidosis involvement from XII International Symposium on Amyloidosis:


---

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### DEFINITION OF ORGAN AND HEMATOLOGIC RESPONSE AND PROGRESSION CRITERIA*

#### Organ Response and Progression Criteria

<table>
<thead>
<tr>
<th>Organ</th>
<th>Response</th>
<th>Progression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart</td>
<td>NT-proBNP response (&gt;30% and &gt;300 ng/L decrease in patients with baseline NT-proBNP ≥650 ng/l) or NYHA class response (≥2 class decrease in subjects with baseline NYHA class 3 or 4)</td>
<td>NT-proBNP progression (&gt;30% and &gt;300 ng/L increase)(^a) or cTn progression (≥33% increase) or Ejection fraction progression (≥10% decrease)</td>
</tr>
<tr>
<td>Kidney</td>
<td>50% decrease (at least 0.5 g/d) of 24-h urine protein (urine protein must be &gt;0.5 g/d pretreatment). Creatinine and creatinine clearance must not worsen by 25% over baseline</td>
<td>50% increase (at least 1 g/d) of 24-h urine protein to &gt;1g/d or 25% worsening of serum creatinine or creatinine clearance</td>
</tr>
<tr>
<td>Liver</td>
<td>50% decrease in abnormal alkaline phosphatase value Decrease in liver size radiographically at least 2 cm</td>
<td>50% increase of alkaline phosphatase above the lowest value</td>
</tr>
<tr>
<td>Peripheral nervous system</td>
<td>Improvement in electromyogram nerve conduction velocity (rare)</td>
<td>Progressive neuropathy by electromyography or nerve conduction velocity</td>
</tr>
</tbody>
</table>

#### Hematologic Response and Progression Criteria

<table>
<thead>
<tr>
<th>Response category</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete</td>
<td>Normalization of the free light chain levels and ratio, negative serum and urine immunofixation</td>
</tr>
<tr>
<td>Very good partial</td>
<td>Reduction in the dFLC to &lt;40 mg/L</td>
</tr>
<tr>
<td>Partial</td>
<td>A greater than 50% reduction in the dFLC</td>
</tr>
<tr>
<td>No response</td>
<td>Less than a PR</td>
</tr>
</tbody>
</table>

**Progression**

- From CR, any detectable monoclonal protein or abnormal free light chain ratio (light chain must double)
- From PR, 50% increase in serum M protein to >0.5 g/dL or 50% increase in urine M protein to >200 mg/d (a visible peak must be present)
- Serum free light chain increase of 50% to >100 mg/L

**Abbreviations:** NT-proBNP, N-terminal prohormone of brain natriuretic peptide; cTnT, cardiac troponin; NYHA, New York Heart Association.

* Patients with progressively worsening renal function cannot be scored for NT-proBNP progression.

NCCN Guidelines Version 1.2018
Systemic Light Chain Amyloidosis

Discussion
This discussion is being updated to correspond with the newly updated algorithm. Last updated 08/14/15

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

Overview .................................................................................................................................................................. 2
Initial Diagnostic Workup .................................................................................................................................. 2
Organ Involvement and Response to Treatment ................................................................................................. 3
Primary Treatment ............................................................................................................................................... 3
References ......................................................................................................................................................... 8
Overview

Primary systemic light chain amyloidosis is typically characterized by decreased numbers of monoclonal plasma cells in the bone marrow compared to multiple myeloma, however, the protein produced by these plasma cells has an affinity for visceral organs (such as kidney, heart, liver, and spleen), and this protein causes related end-organ dysfunction. Even though patients with this disease typically have a low burden of monoclonal plasma cells their survival is often poor due to the end organ damage by the amyloid protein. The therapy of systemic light chain amyloidosis is directed to recovering the function of the target organs by targeting the abnormal plasma cell clone.

Initial Diagnostic Workup

The initial diagnostic workup includes a history and physical (H & P) examination and evaluation of orthostatic vital signs. The following biological assessments are carried out: complete blood counts (CBC) with differential including platelet counts, blood urea nitrogen (BUN) content, serum creatinine, coagulation studies and electrolytes. Patients with systemic light chain amyloidosis are at risk for developing acquired factor X deficiency due to binding of factor X to amyloid fibrils. This deficiency typically responds to treatment of the underlying amyloidosis. Screening by serum electrophoresis alone may be inadequate, as it does not show a monoclonal spike in nearly 50% of cases. Therefore, all patients should undergo immunofixation electrophoresis of both serum and urine, which could detect a monoclonal (M) component. The work-up should also include quantification of proteinuria by 24 hour urine collection and measurement of creatinine clearance. The measurement of circulating serum free light chain (FLC) is a powerful diagnostic complement as the majority of patients with light chain amyloidosis will have abnormalities of the kappa or lambda chains or the kappa/lambda ratio. Additionally the FLC analysis is necessary to determine the hematologic response to therapy. Free light chains are cleared by the kidney therefore renal insufficiency increases the concentrations of FLC. In that case, the kappa/lambda ratio or the difference between involved and uninvolved free light chains should be monitored.

The diagnosis of amyloidosis requires the identification of amyloid deposits in tissues either by aspiration of abdominal subcutaneous fat and/or biopsy of the organs involved and the characterization of amyloidosis as a systemic light chain type requires the demonstration of the underlying plasma cell clone. Amyloid deposits are identified by bone marrow aspiration and biopsy followed by Congo red staining. Congo red staining of the subcutaneous fat aspirate is a reliable and noninvasive test reported to identify amyloid deposits in approximately 90% of patients. The monoclonal plasma cell population can be detected in bone marrow aspirates by immunohistochemical staining of kappa and lambda chains. Immunohistochemistry for transthyretin or the serum amyloid A component should be performed if kappa and lambda stains are negative. The stroma or blood vessels have been reported to be positive for amyloid in 60% of patients. Identification of light chains in the serum or urine without confirmation of the amyloid composition in tissue is not adequate as patients with other forms of amyloidosis may have an unrelated MGUS. Therefore it is essential to confirm that the amyloid deposits are composed of light chains by immunohistochemical methods, electron microscopy, or mass spectrometry. The NCCN panel members recommend mass spectrometry only if clinically indicated such as in cases where two potential amyloid precursor proteins are present including patients with monoclonal gammopathies who are African-American or elderly men, or who have dominant peripheral or autonomic neuropathy, family histories.
of amyloidosis, or coexisting inflammatory disorders. Since the treatment is different in the various types of amyloidosis, it is essential to confirm that patients have primary systemic amyloidosis rather than hereditary amyloidosis, senile amyloidosis, or secondary amyloidosis. Genetic testing especially for African-American and patients with peripheral neuropathy must be done to identify the specific mutation in the hereditary forms and avoid misdiagnosis.9,13

Specialized tests based on organ involvement
Majority of the patients present with one or more organs affected by amyloidosis. The consensus criteria for organ involvement have been recently updated at the 12th International Symposium on Amyloidosis.14

Cardiac involvement is diagnosed by imaging techniques such as echocardiography (EKG), echocardiogram, chest x-ray, and cardiovascular MRI in certain circumstances. Cardiovascular MRI has been successfully used for the diagnosis and prognosis of amyloid cardiomyopathy.15 Cardiac biomarkers in the serum provide a quantitative assessment of cardiac dysfunction (troponin I or T) and cardiac stress (brain natriuretic peptide (BNP) or NT-proBNP) are important predictors of outcome in amyloidosis as well as part of the cardiac response criteria.16,17

Liver and gastrointestinal (GI) involvement is diagnosed by elevated serum alkaline phosphatase levels and bilirubin; performing stool guaiac tests to detect fecal occult blood; gastric emptying scan if gastroparesis is present; and ultrasound or CT scan to determine craniocaudal liver span.

An electromyogram (EMG) or nerve conduction testing can be performed if the patient has significant peripheral neuropathy to confirm peripheral nervous system involvement.

Endocrine tests (thyroid stimulating hormone and cortisol levels) and pulmonary function tests may be performed if involvement of the endocrine system or lungs is suspected.

Organ Involvement and Response to Treatment
The first international consensus opinion for the definition of organ involvement and response to treatment for systemic light chain amyloidosis was published in 2005.18 These criteria has been recently updated14,19 and the tables with definition for hematologic and organ involvement and criteria for response to treatment are included in the NCCN algorithms.

Primary Treatment
All current strategies include systemic therapy to destroy the plasma cells responsible for the synthesis of immunoglobulin light chain. Several active regimens are now available for the treatment of systemic light chain amyloidosis. Most are those derived from the treatment of multiple myeloma. The goals of therapy include eliminating the misfolded amyloid light chains as promptly as possible, minimizing treatment toxicity, and supporting the function of the damaged organs. The consensus criteria for hematologic and organ response have been recently updated at the 12th International Symposium on Amyloidosis.14

High-dose melphalan followed by stem cell transplant
High-dose melphalan followed by stem cell transplant (SCT) is one of the therapeutic options listed by the NCCN panel. However, patients have to be carefully selected as this treatment modality is associated with significant treatment-related mortality.20-25 The extent of organ involvement is considered as predictor of outcome.23,26,27

In eligible patients, high-dose chemotherapy along with stem cell support has been associated with higher response rates and improved
overall survival (OS) than standard chemotherapy. The best outcomes following SCT have been reported in patients who achieve complete response (CR) to high-dose primary chemotherapy including improvement of organ-related disease. The most significant leading indicator of the durability of treatment benefits is the depth of the response to therapy measured by the lowest post-transplantation serum free light chain level.

There are a number of groups that have evaluated dose-adjustment of the high dose melphalan during a transplant based on factors such as age, number of organs involved and presence or absence of cardiac involvement. The reported toxicity of reduced-dose of melphalan is substantially less than high dose. However it should be noted that higher doses of melphalan are associated with a higher CR rate, and improved OS and event-free survival (EFS). Long-term follow-up study of the 74 patients who underwent SCT found that 32 (43%) survived greater than 10 years. The baseline characteristics identified in the study as statistically and significantly different between those who survived long term versus those who did not are 1) the number of organs involved; 2) interventricular septal thickness; 3) total cholesterol; and 4) urine total protein.

Melphalan/Dexamethasone
Melphalan and dexamethasone regimen has also been used in the management of systemic light chain amyloidosis. It has shown promising results in patients with primary amyloidosis who are ineligible for SCT. A small study reported hematologic response in 67% (n = 31) and complete remission in 33% (n = 15) treated with melphalan and high-dose dexamethasone in a median of 4.5 months. Improvement in organ function was seen in 48% (n = 22). The updated results reported that the CR induced by melphalan and high-dose dexamethasone was maintained in 70% of the patients for up to 3 years, and survival at a median follow-up of 5 years was about 50%.

The French Myeloma Collaborative Group compared melphalan and dexamethasone to high-dose melphalan followed by SCT in a randomized trial and found no significant differences for hematologic or organ responses. In a recent update, with a longer follow-up, the authors found that survival or remission duration were not statistically different between melphalan and dexamethasone versus high-dose melphalan followed by SCT even after eliminating treatment related mortality in from SCT arm.

Dexamethasone/Alpha-interferon
In a multicenter, cooperative group trial (n = 93), patients were treated with induction therapy with dexamethasone, followed by maintenance therapy with dexamethasone and alpha interferon. Complete hematologic response was seen in 24% and improvement of organ dysfunction in 45% of the evaluable patients; overall median survival was 31 months; and 2-year survival rate was 60%.

Thalidomide/Dexamethasone
Thalidomide in combination with dexamethasone was studied in a small group of patients. Only 11 patients out of the 31 enrolled tolerated 400 mg/day of thalidomide for a median of 5.7 months; 20 patients experienced toxicity of grade 3 or more. This combination although active is associated with substantial toxicity.

Cyclophosphamide/Thalidomide/Dexamethasone
Thalidomide has also been combined with cyclophosphamide, and dexamethasone. Wechalekar et al studied the use of oral regimen of cyclophosphamide, thalidomide, and dexamethasone (CTD) in phase II study involving 75 patients with advanced systemic light chain
Systemic Light Chain Amyloidosis

amyloidosis, including 44 patients with clonal relapse after prior therapy. Elderly patients (> 70 years), those with heart failures, and those with significant fluid overload received a risk attenuated CTD regimen (CTDa). The study reported overall hematologic response in 74% (48 out of 65 evaluable patients treated with either CTD or CTDa), including complete responses in 21% (n = 14) and partial responses in 53% (n = 34). About 8% (n = 6) discontinued treatment due to toxicities within 8 weeks of initiating therapy. Grade 2 toxicities were reported in 52% (n = 39) of patients and treatment related mortality was 4% (n = 3). Among patients with complete and partial hematologic response, the three year estimated OS based on the data was 100% and 82% respectively.

Lenalidomide/Dexamethasone

Lenalidomide is an analogue of thalidomide. Phase II studies have shown lenalidomide in combination with dexamethasone is active in the treatment of patients with systemic light chain amyloidosis, including those with relapsed/refractory disease. Common adverse effects reported in patients on the study included rash, cytopenia, and fatigue. The incidence of dermatologic adverse effects with combination of lenalidomide and dexamethasone was found to be higher in patients with amyloidosis compared to those with myeloma. In addition, progressive azotemia and serious cardiac and renal toxicity has been reported in patients with amyloidosis, warranting careful monitoring of patients on this regimen.

Lenalidomide/cyclophosphamide/dexamethasone

In phase II study, 35 patients of who 24 were newly diagnosed with systemic amyloidosis, were treated with the combination of lenalidomide, cyclophosphamide, and dexamethasone.

About 63% of patients had cardiac involvement; 3% had stage III disease and 28% had ≥ 3 organs involved. The overall hematologic response rate to lenalidomide, cyclophosphamide and dexamethasone was 60%, including 40% with very-good partial response or better. Assessment of response using serum FLC assay, revealed 77% of patients had a hematologic response and 29% of these patients showed organ responses. The median hematologic progression-free survival reported in this trial was 28.3 months and the median overall survival was 37.8 months. Hematologic toxicity was the predominant adverse event reported in this study.

Pomalidomide/dexamethasone

Pomalidomide, like lenalidomide is an analogue of thalidomide. The safety and efficacy of pomalidomide and dexamethasone was studied in a prospective phase II study. Patients with previously treated systemic light chain amyloidosis (n = 33) were enrolled in the trial and upon treatment with pomalidomide and dexamethasone, confirmed response was reported in 48% (n = 16) with a median time to response of 1.9 months. The median overall was 28 months and progression-free survival rates was 14 months; the overall and progression-free survival rate at one year were 76% and 59%, respectively.

Bortezomib

Bortezomib is rapidly active in systemic light chain amyloidosis with high rates of hematologic and organ responses. Clinical studies have reported bortezomib with or without dexamethasone to be active in untreated and relapsed amyloidosis. The National Amyloidosis Center in Britain reported on 20 relapsed or refractory patients treated with bortezomib. A hematologic response was seen in 80% (n = 16) of patients, 15% (n = 3) achieved CR and 65% (n =13) achieved a partial response. In a multicenter phase I/II dose-escalation study of
bortezomib, hematologic responses were seen in 15% (15 out of 30 evaluable pretreated patients) with CR rate of 20% (n = 6).56 Bortezomib was well tolerated at doses up to 1.6 mg/m² on a once-weekly schedule and 1.3 mg/m² on a twice-weekly schedule.57 The median time to response was 1.2 months. Although once-weekly and twice-weekly bortezomib was seen to be generally well tolerated in the study, the once-weekly bortezomib regimen was associated with lower neurotoxicity.57

**Bortezomib/Dexamethasone**

Efficacy of bortezomib in association with dexamethasone was also evaluated in small study of 18 patients included those who had relapsed or progressed on prior therapies. Out of 16 evaluable patients, hematologic response was seen in 94% (n = 14) including complete response in 44% (n = 7).51 A phase II clinical trial studied the bortezomib and dexamethasone adjuvant therapy in 21 patients not achieving a CR post-SCT. At 1 year post-SCT out of 12 evaluable patients, there was an overall response rate of 92% (n= 11), 67% (n = 8) achieved a CR and 50% (n = 6) had organ responses.58 Data from three international centers from 94 patients (18 previously untreated) treated with bortezomib reported a 71% (67 out of 93 patients) overall response rate with CR in 25% (47% CR was in previously untreated patients).53

**Bortezomib/Melphalan/Dexamethasone**

Combining weekly bortezomib with melphalan in small series of patients yielded hematologic response rates of 94%.59 Bortezomib in combination with melphalan and dexamethasone was evaluated in a small phase II trial and results with a best-response rate of over 80% and a CR rate of 42%.60 These encouraging preliminary results and the fact that bortezomib in combination oral melphalan and prednisone has improved survival in patients with myeloma had led to an ongoing phase III trial is comparing bortezomib in combination with melphalan and dexamethasone to melphalan and dexamethasone as frontline therapy in patients with systemic amyloidosis.

A collaborative study at three large European amyloid centers analyzed the outcomes of 428 patients treated with oral CTD; oral melphalan/dexamethasone; bortezomib/dexamethasone with or without an alkylator; cyclophosphamide/lenalidomide/dexamethasone; or autologous SCT as first line treatment for systemic light chain amyloidosis. The organ and NT-proBNP responses were found highest in the group treated with bortezomib/dexamethasone (53% and 32%), followed by CTD (38% and 12%), autologous SCT (30%), melphalan/dexamethasone (23% and 19%) and cyclophosphamide/lenalidomide/dexamethasone (12% and 0%).61

**Cyclophosphamide/Bortezomib/Dexamethasone**

Recently, the combination of cyclophosphamide, bortezomib and dexamethasone (CyBORD) is reported with high hematologic response rates and CR in two independent studies.62,63 Mikhael et al reported analysis of 17 patients, 10 had no previous therapy. The patients were treated with weekly administration CyBORD before autologous transplantation, as an alternate to transplantation for transplant ineligible patients, or as salvage therapy for patients with relapsed disease. The hematological responses were seen in 94% and CR rate was 71%. The median duration of response was 22 months. Organ response was observed in 50% of the patients with renal involvement. Three patients originally ineligible for autologous SCT, became eligible after treatment with CyBORD.62

In the study by Venner et al, 43 patients were treated with biweekly administration of CyBORD, Twenty out of the 43 patients were
treatment naïve. The hematologic response rate was 81.4% with a CR rate of 39.5%. Due to the biweekly administration, peripheral neuropathy was seen in 30% of the patients. A small retrospective study of patients newly diagnosed with systemic amyloidosis and multiple myeloma treated with the CyBorD regimen containing subcutaneous bortezomib reported a high response rate and minimal toxicity. These results need to be validated in prospective trials.

NCCN Recommendations for Primary Treatment
The NCCN panel members recommend that treatment of systemic light chain amyloidosis should be in the context of a clinical trial when possible because data are insufficient to identify optimal treatment of the underlying plasma cell disorder.

Based on the evidence discussed above, the current NCCN Guidelines list the following as therapeutic considerations for management of patients with systemic light chain amyloidosis (all category 2A recommendation) along with best supportive care: high-dose melphalan followed by autologous SCT; oral melphalan and dexamethasone; dexamethasone in combination with alpha-interferon; thalidomide plus dexamethasone; lenalidomide and dexamethasone; Lenalidomide/cyclophosphamide/dexamethasone; pomalidomide and dexamethasone; bortezomib with or without dexamethasone; bortezomib with melphalan plus dexamethasone; cyclophosphamide, thalidomide, and dexamethasone; and cyclophosphamide, bortezomib, and dexamethasone.

The treatment options are listed alphabetically in the NCCN Guidelines and do not indicate or imply preference. As the optimal therapy for systemic light chain amyloidosis still remains unknown, the NCCN Panel Members strongly encourage treatment in the context of a clinical trial when possible.
References


transplant in systemic AL amyloidosis [abstract]. J Clin Oncol 2009;27
(Suppl-15):Abstract 8540. Available at:
http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8540.

(M)/dexamethasone (D)/bortezomib in AL amyloidosis [abstract]. J Clin
Oncol 2010;28:Abstract 8024. Available at:
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8024.

60. Zonder J, Sanchorawala V, Snyder R. Rapid haematologic and
organ responses in patients with AL amyloid treated with bortezomib
plus melphalan and dexamethasone [abstract]. Amyloid 2010;17(s1):86.

Collaborative Study of Treatment Outcomes In 428 Patients with
Available at:
http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/988.

rapid and complete hematologic response in patients with AL
amyloidosis. Blood 2012;119:4391-4394. Available at:

63. Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib,
and dexamethasone therapy in AL amyloidosis is associated with high
clonal response rates and prolonged progression-free survival. Blood
2012;119:4387-4390. Available at:

64. Shah GL, Kaul E, Fallo S, et al. Subcutaneous Bortezomib in
Combination Regimens in Newly Diagnosed Patients with Myeloma or
Systemic AL Amyloidosis: High Response Rates and Minimal Toxicity.
ASH Annual Meeting Abstracts 2012;120:2968-. Available at:
http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/2
1/2968.